\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes Climate, Energy, MobilityThe DUT partnership would like to receive input from stakeholders on the future calls 2025-26 for R&I projects. This survey is open to anyone with a specal interest in urban transitions so not just limited to the partners.
You can find all the details here and the survey is open until the 19th of January.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Research Infrastructures Digital, Industry & Space Agro-Food, Environment
The Central European Research Infrastructure Consortium (CERIC-ERIC) is calling for proposals for coordinated access to more than 60 instruments and support laboratories for research in all fields of materials, biomaterials and nanotechnology. A detailed description of the facilities available in CERIC can be found here. CERIC... read more
Security Digital, Industry & Space Cybersecurity
The European Cybersecurity Competence Centre (ECCC) has opened a call for tenders to set up a European testing infrastructure for post-quantum cryptography (PQC). Open to applicants across the European Economic Area, the contract is worth EUR 25 million and covers IT services including development and support. The submission deadline is 20 Februa... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
